David Devos obtained his Doctor of Neurology and Doctor of Neuroscience degrees from the University of Lille, Lille, France. Between 2002 and 2010, he worked as a hospital physician in the Department of Neurology, University hospital of Lille, where he is now a Professor in Medical Pharmacology. He is coordinating the neurogenetic center of Lille (Spinocerebellar ataxia, spastic paraplegia, Neurodegeneration with Brain Iron Accumulation). He is consultant and running research at the expert center of Parkinson’s disease (PD) and Amyotrophic Lateral Sclerosis (ALS) of Lille. He is co-coordinating the French network of PD (NS-Park-F-CRIN) and of ALS (ACT4ALS). His main research interests are preclinical and clinical studies of disease-modifying strategies in neurodegenerative disease and particularly PD and ALS for which he received several prices including the European Pharmacology Scientific Award EACPT. He participated in 30 studies including 14 multicenter trials and 14 as Coordinator (10 in progress), 4 European Commission funded projects (H2020) including 2 in neurosciences (iron, ferroptotic cell death), 1 large European clinical trial FAIRPARK-2 and 1 on diagnosis on Covid-19. He published about 200 publications. He obtained 6 patents leading to 3 industrial transfers for which he launched and cofounded 3 Start up (InBrain Pharma for Brain Infusion, InVenis Biotherapies for platelet-based biotherapies and CorDial-IT for diagnosis tools).